You are viewing the site in preview mode
Skip to main content
|
Demographic variable
|
Deferasirox FCT, N = 53
|
|---|
|
Age (years), mean (SD)
|
32.9 (13.16)
|
|
Age category (years), n (%)
|
|
< 18
|
3 (5.7)
|
|
≥ 18 to < 50
|
46 (86.8)
|
|
≥ 50 to < 65
|
1 (1.9)
|
|
≥ 65a
|
3 (5.7)
|
|
Sex, n (%)
|
|
Male
|
18 (34.0)
|
|
Female
|
35 (66.0)
|
|
BMI (kg/m2), mean (SD)
|
23.1 (3.81)
|
|
Predominant race, n (%)
|
|
Caucasian
|
50 (94.3)
|
|
Asian
|
1 (1.9)
|
|
Otherb
|
2 (3.8)
|
|
Main underlying disease, n (%)
|
|
MDS IPSS-R risk stratification
|
4 (7.5)
|
|
Very low risk
|
2 (3.8)
|
|
Low risk
|
1 (1.9)
|
|
Intermediate risk
|
1 (1.9)
|
|
TDT
|
49 (92.5)
|
|
Time since diagnosis (years), mean (SD)
|
27.1 (9.97)
|
|
MDS
|
5.1 (1.91)
|
|
TDT
|
28.9 (7.99)
|
|
Prior ICT (received during the ECLIPSE study), n (%)
|
|
Deferasirox DT
|
27 (50.9)
|
|
Deferasirox FCT
|
26 (49.1)
|
|
Last ICT received before deferasirox FCT in the current study, n (%)
|
|
Deferiprone
|
5 (9.4)
|
|
Deferoxamine and deferiprone
|
3 (5.7)
|
|
Deferasirox monotherapy
|
45 (84.9)
|
|
Transfusion history
|
|
Total number of transfusions received over the past 12 months, mean (SD)
|
24.8 (10.52)
|
|
Time since last blood transfusion (days), mean (SD)
|
8.0 (10.21)
|
|
Baseline serum ferritin (µg/L), mean (SD)
|
2524 (1746)
|
- BMI body mass index, DT dispersible tablet, FCT film-coated tablet, ICT iron chelation therapy, IPSS-R Revised International Prognostic Scoring System, MDS myelodysplastic syndrome, SD standard deviation, TDT transfusion-dependent thalassemia
- aThe oldest patient was 77 years old
- bOther included two patients who self-identified as white
